Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPHERE: Phosphocreatine in Medical Emergency Team–treated Ward Patients
2022-003703-16Phase 3Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jan 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in clinical deterioration comparing Phosphocreatine (Neoton) with Placebo / standard care (2 arms). Primary endpoint: Days alive and out of hospital at 30 days (DAOH30). Started Jan 2023; status: active.
02
Drugs
phosphocreatine
03
Conditions
clinical deterioration
Beyond the preview
Go deeper on 2022-003703-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003703-16.